Therefore, any attempt to improve the evaluation of PD-L1 expression in tumor tissue should ideally be no more invasive than the standard biopsy procedure and not consume more patient specimen than a standard immunohistochemitry (IHC) evaluation. This evidence concerns the gene CD274 and neoplasm.